Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18127
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSakthianandeswaren, Anuratha-
dc.contributor.authorParsons, Marie J-
dc.contributor.authorMouradov, Dmitri-
dc.contributor.authorMacKinnon, Ruth N-
dc.contributor.authorCatimel, Bruno-
dc.contributor.authorLiu, Sheng-
dc.contributor.authorPalmieri, Michelle-
dc.contributor.authorLove, Christopher-
dc.contributor.authorJorissen, Robert N-
dc.contributor.authorLi, Shan-
dc.contributor.authorWhitehead, Lachlan-
dc.contributor.authorPutoczki, Tracy L-
dc.contributor.authorPreaudet, Adele-
dc.contributor.authorTsui, Cary-
dc.contributor.authorNowell, Cameron J-
dc.contributor.authorWard, Robyn L-
dc.contributor.authorHawkins, Nicholas J-
dc.contributor.authorDesai, Jayesh-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorErnst, Matthias-
dc.contributor.authorStreet, Ian-
dc.contributor.authorBuchert, Michael-
dc.contributor.authorSieber, Oliver M-
dc.date2018-06-07-
dc.date.accessioned2018-08-07T06:30:04Z-
dc.date.available2018-08-07T06:30:04Z-
dc.date.issued2018-08-
dc.identifier.citationCancer discovery 2018; 8(8): 988-1005-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18127-
dc.description.abstractADP-ribosylation is an important posttranslational protein modification that regulates diverse biological processes, controlled by dedicated transferases and hydrolases. Here, we show that frequent deletions (∼30%) of the MACROD2 mono-ADP-ribosylhydrolase locus in human colorectal cancer cause impaired PARP1 transferase activity in a gene dosage-dependent manner. MACROD2 haploinsufficiency alters DNA repair and sensitivity to DNA damage and results in chromosome instability. Heterozygous and homozygous depletion of Macrod2 enhances intestinal tumorigenesis in ApcMin/+ mice and the growth of human colorectal cancer xenografts. MACROD2 deletion in sporadic colorectal cancer is associated with the extent of chromosome instability, independent of clinical parameters and other known genetic drivers. We conclude that MACROD2 acts as a haploinsufficient tumor suppressor, with loss of function promoting chromosome instability, thereby driving cancer evolution.Significance: Chromosome instability (CIN) is a hallmark of cancer. We identify MACROD2 deletion as a cause of CIN in human colorectal cancer. MACROD2 loss causes repression of PARP1 activity, impairing DNA repair. MACROD2 haploinsufficiency promotes CIN and intestinal tumor growth. Our results reveal MACROD2 as a major caretaker tumor suppressor gene. Cancer Discov; 8(8); 988-1005. ©2018 AACR.See related commentary by Jin and Burkard, p. 921This article is highlighted in the In This Issue feature, p. 899.-
dc.language.isoeng-
dc.titleMACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors.-
dc.typeJournal Article-
dc.identifier.journaltitleCancer discovery-
dc.identifier.affiliationSystems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Surgery, The University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationVictorian Cancer Cytogenetics Service, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia-
dc.identifier.affiliationDepartment of Medicine, The University of Melbourne (St Vincent's Hospital), Fitzroy, Victoria, Australia-
dc.identifier.affiliationDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Pathology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia-
dc.identifier.affiliationInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia-
dc.identifier.affiliationHistology Facility, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia-
dc.identifier.affiliationDrug Discovery Biology, The Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia-
dc.identifier.affiliationOffice of the Deputy Vice-Chancellor (Research), The University of Queensland, Brisbane, Queensland, Australia-
dc.identifier.affiliationFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia-
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, LaTrobe University, Heidelberg, Victoria, Australia-
dc.identifier.affiliationCancer Therapeutics Cooperative Research Centre, Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Biochemistry & Molecular Biology, Monash University, Clayton, Victoria, Australia-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1158/2159-8290.CD-17-0909-
dc.identifier.orcid0000-0003-0294-5051-
dc.identifier.orcid0000-0002-6399-1177-
dc.identifier.pubmedid29880585-
dc.type.austinJournal Article-
local.name.researcherErnst, Matthias
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Dec 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.